Bernstein Reiterates Outperform Rating on Eli Lilly (LLY)

Bernstein SocGen Group analyst Courtney Breen reiterated an Outperform rating and $1,100.00 price target on Eli Lilly (NYSE: LLY).

The analyst commented: "Greater confidence in orfo as the leading oral GLP-1; After EASD we are using this note to provide our reflections on some of the key data presented, as well as the insights gained from our discussions with a key obesity opinion leader & LLY’s sell-side event. Please reach out if you’d like to discuss these insights further. Generally the conference reaffirmed data expectations from prior results (for both LLY & NOVO, covered by Cespedes). Notably, physician conversations highlighted much more patient focus - particularly the right product for the right patient, recognizing variation in patient needs. And in terms of trial design, the reduced willingness to accept placebocontrolled trials, which is particularly important as we think about future pivotal development programs."

For an analyst ratings summary and ratings history on Eli Lilly click here. For more ratings news on Eli Lilly click here.

Shares of Eli Lilly closed at $746.98 yesterday.

You May Also Be Interested In

• Wolfe Research Starts SpaceX (SPCX) at Outperform
• EnerSys (ENS) PT Raised to $280 at BTIG
• Piper Sandler Assumes Cass Information Systems, Inc. (CASS) at Neutral